Scythian Biosciences Corp. (TSXV: $SCYB.V) Applies for Listing of Common Stock on NASDAQ

TORONTO - August 30, 2017 (Investorideas.com Newswire) Scythian Biosciences Corp. (TSXV: SCYB) (the "Company") is pleased to announce that it has submitted an initial listing application to list its common shares on the NASDAQ Capital Market.

The Company's common shares have traded on the TSX Venture Exchange (the "TSXV") under the symbol "SCYB" since August 8, 2017.

"We look forward to broadening our shareholder base by dual listing on Canada's TSXV and on the NASDAQ exchange so that investors in the United States may more easily purchase and sell our securities on the aftermarket," said Jonathan Gilbert, Chief Executive Officer.

There can be no assurance that NASDAQ will approve the Company's initial listing application or that a market for the Company's common shares in the United States will develop.

Read this news in full at http://www.investorideas.com/CO/SCYB/news/2017/08301NASDAQ.asp

About Scythian Biosciences Corp.

Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.

 

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.

 

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995.

 

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

Forward-Looking Statements

This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, its securities, or financial or operating results (as applicable). Although the Company believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including the risk factors discussed in the Filing Statement and the registration statement which are incorporated herein by reference and are available through SEDAR at www.sedar.com and on the SEC EDGAR filing service at www.sec.gov. The forward-looking information contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

 

For further information, please contact:

Scythian Biosciences Corp.
Jonathan Gilbert
CEO
Phone: (212) 729-9208
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Scythian Biosciences Corp. (TSX.V: SCYB)

is a Featured biotech and marijuana company on Investorideas.com

Visit Profile page: http://www.investorideas.com/CO/SCYB/

 

Get News Alerts on Scythian Biosciences Corp.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp

 

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country